Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer
- 31 Downloads
The study aimed to investigate the reason of HCT116 cell resistance to MEK inhibitor, and the combination treatment effects of MEK inhibitor AZD6244 and JAK2/STAT3 inhibitor AG490 on colon cancer in vitro and in vivo, including cell viability, apoptosis, and explore the partial mechanisms focused on AZD6244 promoted the activation of JAK2-STAT3 pathways. In vitro, we examined the HCT116 cell viability by CCK8, cell apoptosis by flow cytometry; Western blot measured p-ERK, p-JAK2, p-STAT3 and STAT3 expression. In vivo, nude mice were subcutaneously injected by HCT116 cells. The tumor volume and weight were detected. HCT116 cell resistance to MEK inhibitor AZD6244, which inhibited the activation of ERK and promoted the activation of JAK2-STAT3 signaling. The combination treatment of AZD6244 and AG490 significantly inhibited cell viability and induced cell apoptosis, and completely inhibited the activation of ERK and JAK2-STAT3 signaling. Combination treatment of AZD6244 and AG490 had a stronger effect than that of AZD6244 as a monotherapy in vitro and in vivo. The treatment of AZD6244 on K-Ras mutations HCT116 cells promoted the activation of JAK2/STAT3 signaling. JAK2/STAT3 inhibitor AG490 synergistically increases effects of AZD6244 on colon cancer in vitro and in vivo. Collectively, these results provide a rationale for combining inhibitors of the JAK/STAT pathway and MEK inhibitors to reduce the potential impact of drug resistance.
KeywordsMEK inhibitors Colon cancer JAK2 STAT3
This work was financially supported by Taizhou Science and Technology Planning Project (2016A33170).
Yanan zhu contributed to the design of the study, served as the study coordinator, and helped to review the manuscript. Jianying Jin designed the study, performed experiments, collected data and wrote the manuscript. Qunyi Guo, Jingjing Xie, Dan Jin helped perform experiments and interpret data. All authors read and approved the final manuscript.
Compliance with Ethical Standards
Conflict of Interest
The authors report no conflict of interest. The authors alone are responsible for the content and writing of this article.
- 1.Zhang W, Tong D, Liu F, Li DW, Li JJ et al (2016) RPS7 inhibits colorectal cancer growth via decreasing HIF-1α-mediated glycolysis. Oncotarget 7:5800–5814 [PubMed: 26735579]Google Scholar
- 2.Lin J, Webber EM, Senger CA, Holmes RS, Whitlock EP (2011) Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. Am J Cancer Res 1:650–662 [PubMed: 21779535]Google Scholar
- 10.Abrams SL, Ruvolo PP, Ruvolo VR, Ligresti G, Martelli AM, Cocco L, Ratti S, Tafuri A, Steelman LS, Candido S, Libra M, McCubrey J (2017) Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. Oncotarget 8(44):76525–76557 [PubMed: 29100331]CrossRefGoogle Scholar
- 13.Jessen WJ, Miller SJ, Jousma E, Wu JQ, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N (2013) MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 123:340–347 [PubMed: 23221341]CrossRefGoogle Scholar
- 16.Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E (2007) Biological characterization of ARRY-142886 (AZD6244), a potent highly selective mitogen-actived protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13:1576–1583 [PubMed: 17332304]CrossRefGoogle Scholar
- 18.Haigis KM, Kendall KR, Wang YF, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T (2008) Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40:600–608 [PubMed: 18372904]CrossRefGoogle Scholar
- 23.Hur EH, Goo BK, Moon J, Choi Y, Hwang JJ, Kim CS, Bae KS, Choi J, Cho SY, Yang SH, Seo J, Lee G, Lee JH (2017) Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells. Oncotarget 8:41387–41400 [PubMed: 28574827]Google Scholar
- 25.Tian F, Yang X, Liu Y, Yuan X, Fan T, Zhang F, Zhao J, Lu J, Jiang Y, Dong Z, Yang Y (2017) Constitutive activated STAT3 is an essential regulator and therapeutic target in esophageal squamous cell carcinoma. Oncotarget 8:88719–88729 [PubMed: 29179470]Google Scholar
- 26.Mohanty SK, Yagiz K, Pradhan D, Luthringer DJ, Amin MB, Alkan S, Cinar B (2017) STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer. Oncotarget 8:85997–86010 PubMed: 29156772]Google Scholar